



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

mKIAA0195 siRNA (m): sc-149454

BACKGROUND

KIAA0195, also known as TMEM94, is a ubiquitously expressed 1,356 amino acid multi-pass membrane protein. KIAA0195 is post-translationally phosphorylated at several serine residues and is alternatively spliced into two isoforms. KIAA0195 is also glycosylated at several residues near its C-terminus. The gene encoding KIAA0195 maps to human chromosome 17, which makes up over 2.5% of the human genome with about 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

REFERENCES

1. Nagase, T., Seki, N., Ishikawa, K., Tanaka, A. and Nomura, N. 1996. Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1. *DNA Res.* 3: 17-24.
2. Nussbaum, R., Vogel, K.J. and Ready, K. 2006-2007. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. *Breast Dis.* 27: 21-50.
3. Dann, R.B., Kelley, J.L. and Zorn, K.K. 2007. Strategies for ovarian cancer prevention. *Obstet. Gynecol. Clin. North Am.* 34: 667-686.
4. Tai, Y.C., Domchek, S., Parmigiani, G. and Chen, S. 2007. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J. Natl. Cancer Inst.* 99: 1811-1814.
5. Yan, J., Jiang, J., Lim, C.A., Wu, Q., Ng, H.H. and Chin, K.C. 2007. BLIMP1 regulates cell growth through repression of p53 transcription. *Proc. Natl. Acad. Sci. USA* 104: 1841-1846.
6. Daub, H., Olsen, J.V., Bairlein, M., Gnad, F., Oppermann, F.S., Körner, R., Greff, Z., Keri, G., Stemmann, O. and Mann, M. 2008. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. *Mol. Cell* 31: 438-448.
7. Oppermann, F.S., Gnad, F., Olsen, J.V., Hornberger, R., Greff, Z., Keri, G., Mann, M. and Daub, H. 2009. Large-scale proteomics analysis of the human kinome. *Mol. Cell. Proteomics* 8: 1751-1764.

CHROMOSOMAL LOCATION

Genetic locus: 2310067B10Rik (mouse) mapping to 11 E2.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

mKIAA0195 siRNA (m) is a pool of 2 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see mKIAA0195 shRNA Plasmid (m): sc-149454-SH and mKIAA0195 shRNA (m) Lentiviral Particles: sc-149454-V as alternate gene silencing products.

For independent verification of mKIAA0195 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149454A and sc-149454B.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

mKIAA0195 siRNA (m) is recommended for the inhibition of mKIAA0195 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor mKIAA0195 gene expression knockdown using RT-PCR Primer: mKIAA0195 (m)-PR: sc-149454-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.